Plasma Amyloid-[beta] Oligomerization Tendency Predicts Amyloid PET Positivity

• Published in: Clinical interventions in aging Vol. 16; p. 749
• Main Authors: Pyun, Jung-Min, Ryu, Ji Sun, Lee, Ryan, Shim, Kyu Hawn, Youn, Young Chul, Ryoo, Nayoung, Han, Sang-Won, Park, Young Ho, Kang, Sungmin, An, Seong Soo A, Kim, SangYun
• Format: Journal Article
• Language: English
• Published: Dove Medical Press Limited 30-04-2021
• Subjects: Alzheimer's disease; Amyloid beta-protein; Chemical properties; Diagnosis; Health aspects; Measurement; Neurological research; Oligomers; PET imaging; Physiological aspects; South Korea
• ISSN: 1178-1998
• DOI: 10.2147/CIA.S312473

Purpose: Among other emerging amyloid-targeting blood-based biomarkers, Multimer Detection System-Oligomeric Amyloid-[beta] (MDS-OAP) measures dynamic changes in concentration of oligomeric amyloid-[beta] (OAP), which is considered the main pathogenic culprit of Alzheimer's disease (AD), in plasma after spiking with synthetic amyloid-[beta] (AP). We aimed to investigate the predictability of MDS-OA[beta] on amyloid positron emission tomography (PET) positivity. Patients and Methods: A total of 96 subjects who visited Seoul National University Bundang Hospital for medical check-up complaining of cognitive decline and had undergone extensive medical assessment were recruited. Amyloid statuses were dichotomized into positive or negative based on visual assessment of amyloid PET. Plasma OA[beta] concentration was measured by MDS-OA[beta]. In the previous validation study, 0.78ng/mL was established as the cut-off value and the plasma OA[beta] concentration higher than or equal to the cut-off value was defined as MDS-OA[beta] positive. Results: MDS-OA[beta] positivity could discriminate amyloid PET positivity with the AUC value of 0.855 (95% CI 0.776-0.933). Adding MDS-OA[beta] positivity to prediction models including age, MMSE score, and APOE [epsilon]4 status improved performance up to the AUC value of 0.926 (95% CI 0.871-0.980). Conclusion: The A[beta] oligomerization tendency in plasma could predict amyloid PET positivity with high performance, and, when it is combined with age, MMSE score, and APOE [epsilon]4 status, predictability was improved substantially. This suggests the potential of MDS-OA[beta] as a useful initial stage test in the clinical and research fields of AD. Keywords: multimer detection system-oligomeric amyloid-[beta], A[beta] oligomer, predictability, amyloidopathy, blood-based biomarker